Inbal H, Hirschfield GM. Primary biliary cholangitis: pathophysiology. Clin Liver Dis. 2024;28:79–92

Article  Google Scholar 

Faisal MS, Gonzalez HC, Gordon SC. Primary biliary cholangitis: epidemiology, diagnosis, and presentation. Clin Liver Dis. 2024;28:63–77

Article  PubMed  Google Scholar 

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145–172

Article  Google Scholar 

Corpechot C, Carrat F, Bahr A, et al. The efect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128:297–303

Article  CAS  PubMed  Google Scholar 

Shuo Z, Xixi T, Li W, et al. Downregulation of programmed death-1 pathway promoting CD8 + T cell cytotoxicity in primary biliary cholangitis. Dig Dis Sci. 2022;67:2981–2993

Article  Google Scholar 

Michael D, Dominik P, Sainitin D, et al. Auto-aggressive CXCR6 CD8 T cells cause liver immune pathology in NASH. Nature. 2021;592:444–449

Article  Google Scholar 

Haoxian G, Shenglu L, Linxin L, et al. Obeticholic acid and 5β-cholanic acid 3 exhibit anti-tumor effects on liver cancer through CXCL16/CXCR6 pathway. Front Immunol. 2022;13:1095915

Article  Google Scholar 

Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases. Hepatology. 2019;69:394–419

Article  PubMed  Google Scholar 

Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55:1361–1367

Article  CAS  PubMed  Google Scholar 

Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978;379:103–112

Article  CAS  PubMed  Google Scholar 

Meng H, Zhu L, Kord-Varkaneh H, Santos HO, Tinsley GM, Fu P. Effects of intermittent fasting and energy-restricted diets on lipid profile: a systematic review and meta-analysis. Nutrition. 2020;77:110801

Article  CAS  PubMed  Google Scholar 

Treister-Goltzman Y, Yarza S, Peleg R. Lipid profile in mild subclinical hypothyroidism: systematic review and meta-analysis. Minerva Endocrinol (Torino). 2021;46(4):428–440

PubMed  Google Scholar 

Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: practice guidance from the American association for the study of liver diseases. Hepatology. 2019;69(1):394–419

Article  PubMed  Google Scholar 

Nanjundappa RH, Shao K, Krishnamurthy P, et al. Invariant natural killer T cells in autoimmune cholangiopathies: Mechanistic insights and therapeutic implications. Autoimmun Rev. 2023;23:103485

Article  Google Scholar 

Zhao S-X, Li W-C, Fu N, et al. Emperipolesis mediated by CD8 T cells correlates with biliary epithelia cell injury in primary biliary cholangitis. J Cell Mol Med. 2020;24:1268–1275

Article  CAS  PubMed  Google Scholar 

Kira H, Friederike R, Valéa S, et al. The function of the chemokine receptor CXCR6 in the T cell response of mice against Listeria monocytogenes. PLoS ONE. 2014;9: e97701

Article  Google Scholar 

Tse S-W, Radtke AJ, Espinosa DA, et al. The chemokine receptor CXCR6 is required for the maintenance of liver memory CD8⁺ T cells specific for infectious pathogens. J Infect Dis. 2014;210:1508–1516

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mossanen JC, Kohlhepp M, Wehr A, et al. CXCR6 inhibits hepatocarcinogenesis by promoting natural killer T- and CD4 T-cell-dependent control of senescence. Gastroenterology. 2019;156:1877-1889.e4

Article  PubMed  Google Scholar 

Ji-Ye K, Aya I, Shozo H, et al. Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model. Oncol Rep. 2013;29:975–982

Article  Google Scholar 

Tingting Li, Jie P, Hongqi C, et al. CXCR6-based immunotherapy in autoimmune, cancer and inflammatory infliction. Acta Pharm Sin B. 2022;12:3255–3262

Article  Google Scholar 

Qiang G, Ying-Jun Z, Xiao-Ying W, et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res. 2012;72:3546–3556

Article  Google Scholar 

Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021;74(6):1344–1354

Article  CAS  PubMed  Google Scholar 

Takano K, Saeki C, Oikawa T, Hidaka A, Mizuno Y, Ishida J, et al. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate. J Gastroenterol Hepatol. 2020;35(4):663–672

Article  CAS  PubMed  Google Scholar 

Yixuan Li, Jing W, Huan J, et al. Causal association between autoimmune liver disease and Sjögren’s syndrome: A Mendelian randomization study. Int J Rheum Dis. 2024;27: e15151

Article  Google Scholar 

Guatibonza-García V, Gaete PV, Pérez-Londoño A, Puerto-Baracaldo DK, Gutiérrez-Romero SA, Mendivil CO, et al. Poor performance of anti-mitochondrial antibodies for the diagnosis of primary biliary cholangitis in female Colombian patients: a single-center study. World J Gastroenterol. 2021;27(29):4890–4899

Article  PubMed  PubMed Central  Google Scholar 

Chen S, Lv T, Sun G, et al. Reciprocal alterations in circulating and hepatic gamma-delta T cells in patients with primary biliary cholangitis. Hepatol Int. 2022;16(1):195–206

Article  PubMed  Google Scholar 

Hydes TJ, Blunt MD, Naftel J, et al. Constitutive activation of natural killer cells in primary biliary cholangitis. Front Immunol. 2019;10:2633

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anke L, Alexander W, Marlene K, et al. CXCR6 protects from inflammation and fibrosis in NEMO mice. Biochim Biophys Acta Mol Basis Dis. 2019;1865:391–402

Article  Google Scholar 

Alexander W, Christer B, Felix H, et al. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J Immunol. 2013;190:5226–5236

Article  Google Scholar 

Zhang Y, Hu X, Chang J, et al. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol. 2021;21(1):395

Article  PubMed  PubMed Central  Google Scholar 

Zheng L, Qin S, Si W, Wang A, Xing B, Gao R, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science. 2021;374:6474

Article  Google Scholar 

Li X, Gao Z, Chen J, Feng S, Luo X, Shi Y, et al. Integrated single cell and bulk sequencing analysis identifies tumor reactive CXCR6+ CD8 T cells as a predictor of immune infiltration and immunotherapy outcomes in hepatocellular carcinoma. Front Oncol. 2023;1(13):1099385. https://doi.org/10.3389/fonc.2023.1099385.PMID:37593098;PMCID:PMC10430781

Article  Google Scholar 

Wang B, Wang Y, Sun X, Deng G, Huang W, Wu X, et al. CXCR6 is required for antitumor efficacy of intratumoral CD8(+) T cell. J Immunother Cancer. 2021;9:1–13

Article  Google Scholar 

Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450–456

Article  CAS  PubMed  PubMed Central  Google Scholar